Tumor cell DNA and associated macromolecules (DNA)

Tumor cell DNA and associated macromolecules, including histones and topoisomerases, represent a foundational class of therapeutic targets in oncology [1]. DNA carries the essential genetic blueprint for cell survival and proliferation, making it a primary target for cytotoxic chemotherapy in rapidly dividing malignant cells [3]. Therapeutic agents interact with these targets by inducing structural damage—such as covalent cross-links, alkylation, or intercalation—which disrupts the processes of DNA replication and transcription [2][5]. When the extent of DNA damage exceeds the cell's repair capacity, programmed cell death (apoptosis) is triggered [4]. While highly effective, these targets are also present in healthy dividing tissues, leading to significant side effects like bone marrow suppression and gastrointestinal toxicity [1][2]. Modern precision medicine often evaluates the status of DNA repair pathways, such as homologous recombination deficiency, to predict sensitivity to DNA-damaging agents [3]. Sources: [1] National Cancer Institute (NCI) - Alkylating Agents; [2] StatPearls - Cisplatin and Cytotoxic Drugs; [3] Nature Reviews Cancer - DNA-damaging agents; [4] American Cancer Society - Chemotherapy Mechanisms; [5] PubMed - DNA as a target for anticancer drugs.

Other names

Genomic DNAChromatinNuclear DNADeoxyribonucleic acidTumor genome

Drugs targeting tumor DNA act through several mechanisms: alkylating agents form covalent bonds with DNA bases to prevent replication; intercalating agents slide between base pairs to disrupt DNA structure; and topoisomerase inhibitors stabilize DNA-protein complexes, leading to lethal double-strand breaks [1][3][5].